

Supplementary Materials:




Figure S1. Study flow chart.

Table S1. Changes of selected CMR and biochemical parameters between renin-angiotensin-aldosterone blocker users and non-users over the 5-year follow-up.

Changes in	RAAS blockers 0 n = 13	RAAS blockers 1 n = 12	P
native T1, ms	4.28 ± 36.5	-8.47 ± 46.8	0.30
ECV, %	0.023 ± 0.025	0.005 ± 0.043	0.073
Galectin-3, ng/mL	1.35 ± 1.90	-1.31 ± 2.07	0.0068
GDF 15, ng/mL	522.8 ± 718.5	221.0 ± 518.8	0.30
sST2, ng/mL	492.37 ± 459.75	82.16 ± 484.61	0.015
hsTnI, ng/L	-2.20 ± 30.73	-3.71 ± 11.01	0.023
NT-proBNP, ng/L	130.30 ± 268.95	32.67 ± 135.25	0.16

RAAS blockers = blockers of renin-angiotensin-aldosterone system; ECV = extracellular volume; hsTnI = high sensitivity troponin I; sST2 = soluble suppression of tumourigenicity2; GDF 15 = growth differential factor 15; NT-proBNP = N-terminal pro-brain natriuretic peptide. Values are means of change (Δ)±standard deviation. P for difference between the two groups were calculated using Wilcoxon Two Sample test. P values < 0.05 are in bold.